Vaccine Against Varicella
Mostrando 1-10 de 10 artigos, teses e dissertações.
-
1. Genotypes of clinical varicella-zoster virus isolates from Manaus, Brazil
Abstract INTRODUCTION: Vaccination against varicella-zoster virus (VZV) has been effective and safe in countries that routinely administer the vaccine. Brazil began universal VZV vaccination in 2013. This study aimed to identify VZV genotypes present in Manaus, Brazil prior to widespread immunization. METHODS: Vesicular lesions or cerebral-spinal-fluid sam
Rev. Soc. Bras. Med. Trop.. Publicado em: 16/05/2019
-
2. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults
BACKGROUND: Live attenuated varicella vaccines for the prevention of varicella (chickenpox) has been demonstrated both in randomised controlled trials (RCTs) and in population-based immunisation programmes in countries such as the United States. However, many countries do not routinely immunise children against varicella, and exposures continue to occur. Alt
Sao Paulo Medical Journal. Publicado em: 2012
-
3. Uso de modelos de análise de decisão nos programas de vacinação contra a varicela / Use of decision analysis models in the programs of vaccination against varicella
BACKGROUND: The choice between different decision analysis models introduces variability in the results of economic evaluations. Static models do not take into account the indirect effects of vaccination, thus compromising the overall assessment of vaccination benefits. This work developed two models one dynamic and another static to conduct cost-effectivene
Publicado em: 2009
-
4. Avaliações econômicas de programas de vacinação: as estimativas de custos em intervenções preventivas / Economic evaluations of vaccination programmes: cost estimates of preventive interventions
Esta tese representa o aprofundamento do estudo das estimativas de custos, componente integrante e determinante das avaliações econômicas, enquanto parte do projeto de pesquisa Estudos de custo-efetividade da incorporação de novas vacinas à rotina do Programa Nacional de Imunizações: Rotavírus, Varicela, Pneumocócica conjugada, Meningocócica C con
Publicado em: 2009
-
5. Immunization status analysis and evaluation of antibody titers against measles and varicella in 83 chronic renal failure children and adolescents in conservative and dialytic therapy / "Levantamento da situação vacinal e avaliação sorológica para sarampo e varicela de crianças e adolescentes portadores de insuficiência renal crônica em tratamento conservador e dialítico"
A infecção é causa de morbimortalidade no paciente com insuficiência renal crônica (IRC), facilitada pela uremia, que leva a resposta imune insuficiente, inclusive após a vacinação. Foram avaliadas a situação vacinal e a presença de anticorpos para sarampo e varicela, de 83 crianças e adolescentes com IRC. A adesão dos pacientes às vacinas foi
Publicado em: 2004
-
6. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.
Using a plaque reduction assay, we determined the 50% effective doses of six antiviral compounds against low- and high-passage viruses of the KMcC and Oka strains of varicella-zoster virus vaccine. The potency, as indicated by the ranges of 50% effective doses (micrograms per milliliter) of the antiviral compounds, in decreasing order was as follows: (E)-5-(
-
7. Preventing Varicella-Zoster Disease
Varicella-zoster virus (VZV), the cause of chickenpox and shingles, is a pathogen in retreat following the introduction of mass vaccination in the United States in 1995. The live attenuated Oka vaccine, which is safe and immunogenic, gives good protection against both varicella and zoster in the short to medium term. It has undoubtedly been highly effective
American Society for Microbiology.
-
8. Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge.
The IE62 protein, the primary regulatory protein of varicella-zoster virus (VZV) and the major component of the virion tegument, was an effective immunogen in the guinea pig model of VZV infection, whereas the ORF 29 gene product, a nonstructural DNA replication protein, did not elicit protection. All animals immunized with the ORF 29 protein had cell-associ
-
9. Immunogenic glycoproteins of laboratory and vaccine strains of Varicella-Zoster virus.
High-titered antisera were prepared in guinea pigs and rabbits against two strains of varicella-zoster virus (VZV): VZV-32, a low-passage laboratory strain, and VZV-Oka, a vaccine strain attenuated by passage in both human and guinea pig embryo cells. When the animal VZV-immune sera, as well as a human zoster serum, were used to precipitate radiolabeled glyc
-
10. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.
Varicella-zoster virus (VZV) is an attractive candidate for a live-virus vector for the delivery of foreign antigens. The Oka vaccine strain of VZV is safe and effective in humans, and recombinant Oka VZV (ROka) can be generated by transfecting cells with a set of overlapping cosmid DNAs. By this method, the herpes simplex virus type 2 (HSV-2) glycoprotein D